Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of pd-1 immune checkpoint inhibition

HIGHLIGHTS

• who: Dirk Zboralski from the B Pharmaceuticals GmbH, Magnusstrau00dfe, Du2011, Berlin, Germany have published the Article: Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition, in the Journal: (JOURNAL)
• what: The authors demonstrate that combined therapies using radiolabeled FAP-targeting agent 177Lu-FAP-2287, a murine surrogate of 177Lu-FAP-2286, together with PD-1 checkpoint blockade induce tumor inhibition in a FAP expressing MCA205 fibrosarcoma tumor model. This study provides insights into the immunomodulatory functions of FAP-targeted radiotherapy and demonstrates the therapeutic . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.